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Background/Aims
Prokinetics can be used for treating patients with gastroesophageal reflux disease (GERD), who exhibit suboptimal response to proton 
pump inhibitor (PPI) treatment. We conducted a systematic review to assess the potential benefits of combination treatment with PPI 
plus prokinetics in GERD. 
Methods
We searched PubMed, the Cochrane Library, and EMBASE for publications regarding randomized controlled trials comparing 
combination treatment of PPI plus prokinetics to PPI monotherapy with respect to global symptom improvement in GERD (until 
February 2020). The primary outcome was an absence or global symptom improvement in GERD. Adverse events and quality of life 
(QoL) scores were evaluated as secondary outcomes using a random effects model. Quality of evidence was rated using Grading of 
Recommendations, Assessment, Development, and Evaluation (GRADE). 
Results
This meta-analysis included 16 studies involving 1446 participants (719 in the PPI plus prokinetics group and 727 in the PPI 
monotherapy group). The PPI plus prokinetics treatment resulted in a significant reduction in global symptoms of GERD regardless of 
the prokinetic type, refractoriness, and ethnicity. Additionally, treatment with PPI plus prokinetics for at least 4 weeks was found to 
be more beneficial than PPI monotherapy with respect to global symptom improvement. However, the QoL scores were not improved 
with PPI plus prokinetics treatment. Adverse events observed in response to PPI plus prokinetics treatment did not differ from those 
observed with PPI monotherapy.
Conclusions
Combination of prokinetics with PPI treatment is more effective than PPI alone in GERD patients. Further high-quality trials with large 
sample sizes are needed to verify the effects based on prokinetic type.
(J Neurogastroenterol Motil 2021;27:165-175)
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Introduction  
Gastroesophageal reflux disease (GERD) is a common gas-
trointestinal disorder with an estimated worldwide prevalence 
of between 8% and 33%.1 Following the introduction of proton 
pump inhibitors (PPIs) into the drug market, PPIs were used as 
the treatment of choice for GERD. However, approximately 30% 
of the GERD patients treated with the standard doses of PPIs 
continue to manifest symptoms.2 Consequently, the use of other ad-
junctive treatments, including histamine H2 receptor antagonists, 
prokinetics, alginate, and surgery have been suggested in several 
guidelines.3-8 However, the evidences supporting the efficacy of 
such treatments are currently weak. Prokinetics have traditionally 
been found to improve gastrointestinal motility, and therefore have 
been recommended as a first-line treatment in functional dyspepsia 
patients with a postprandial distress subtype.9 Furthermore, several 
studies have reported that when used in combination with PPIs, 
prokinetics show additional benefits with respect to global symptom 
improvement in patients with GERD.10-12 In the Asia-Pacific re-
gion, the consensus regarding the management of GERD has indi-
cated that the uses of prokinetics as an adjunctive therapy with PPIs 
may have a beneficial effect on the treatment of PPI-refractory 
GERD symptoms, although the effect appears to be modest.13,14 In 
Asia, the most commonly used prokinetics are mosapride, itopride, 
and domperidone. However, another prokinetic agent, cisapride, 
has been withdrawn from the market owing to its association with 
fatal heart arrhythmia. Furthermore, although previous studies have 
shown that mosapride, a selective 5-hydroxytryptamine 4 receptor 
agonist, can reduce the episodes of acid reflux and enhance esopha-
geal clearance,15,16 another clinical trial has reported no additional ef-
fect of mosapride when used in combination with PPIs for treating 
GERD.12 Accordingly, for clarifying the efficacy of prokinetics for 
the treatment of patients with GERD, we conducted a systematic 
review of studies that have used prokinetics as an adjunctive therapy 
for the treatment of GERD.
Methods  
Literature Search Strategy
In this study, we performed a systematic review and meta-
analysis of the effects of the combination treatment with PPI plus 
prokinetics and PPI monotherapy on GERD symptoms based on 
the Preferred Reporting Items for Systematic reviews and Meta-
Analyses (PRISMA) principles.17 PubMed, Cochrane Library, 
and EMBASE databases (from inception to February 2020) were 
searched independently by 2 authors of the present review (D.H.J. 
and C.W.H.), using the following search string (Supplementary 
Data). Cited references in published studies were manually and re-
petitively searched to identify other relevant studies. The latest date 
for updating our search was February 14, 2020.
Study Selection
In the first stage of study selection, the title and abstract of ar-
ticles returned by our keyword search were scrutinized to rule out 
articles deemed irrelevant with respect to the purpose of the present 
analysis. Thereafter, we screened the full texts of all selected studies 
in accordance with our stated inclusion and exclusion criteria. The 
inclusion criteria were as follows: (1) a diagnosis of GERD, (2) 
randomized controlled trials with parallel design, (3) comparison of 
PPI plus prokinetics therapy with PPI monotherapy for the treat-
ment of GERD, (4) investigations of adults aged ≥ 18 years; and 
(5) no evidence of disorder (organic, metabolic, or drug-induced) 
to explain the symptoms. The exclusion criteria were as follows: (1) 
studies without a detailed description of the diagnosis of GERD, 
(2) studies in which the objective was to evaluate herbal prokinetic 
agents; (3) studies in which the treatment duration was less than 
7 days, (4) publication in a language other than English, or (5) 
abstract-only publications. 
Data Extraction
Two authors (D.H.J. and C.W.H.) of the present review in-
dependently extracted data from the included studies using a pre-
data extraction form. The titles and abstracts of all included studies 
were reviewed to exclude irrelevant publications. Discrepancies in 
data interpretation were resolved by discussion, re-review of studies, 
or when necessary, consultation with the third author (S.K.L.) of 
this review. The data collected included the following: (1) partici-
pant characteristics, including demographics, recruitment source, 
diagnostic criteria used by the study authors, and GERD subtype; 
(2) interventions details, including the name of the PPI or proki-
netic, dose, and treatment duration; (3) and improvement in reflux 
symptoms before and after the intervention, including the number 
of patients with reflux symptoms, quality of life (QoL), and adverse 
events (AEs). We defined refractory GERD as patients who com-
plained of GERD symptoms despite with once daily dose of PPI 
for at least 8 weeks.
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Primary and Secondary Outcomes
The primary outcome was a global symptom improvement 
of GERD. If more than 1 definition of global symptom improve-
ment was identified, we assessed the most stringent definition of 
global symptom improvement. Although we primarily evaluated 
patient reported outcomes after treatment, if this information was 
not available, we used overall symptom assessment by the physician 
or researcher. If the global symptoms of GERD were not reported, 
we used heartburn or reflux improvement as the outcome measure. 
Secondary outcomes were QoL and AEs.
Methodological Quality
All trials were assessed using Cochrane’s “Risk of Bias (RoB)” 
tool, which includes the following domains: random sequence 
generation (selection bias), allocation concealment (selection bias), 
blinding of participants and personnel (performance bias), blinding 
of outcome assessment (detection bias), incomplete outcome data 
addressed over the short and long terms (attrition bias); selective re-
porting (reporting bias); and other biases. Two authors (D.H.J. and 
C.W.H.) independently assessed the methodological quality of the 
included studies. Any disagreement between the 2 evaluators was 
resolved by discussion.
Statistical Methods
For data analysis, we used Review Manager version 5.3 (Rev-
Man for Windows 7; the Nordic Cochrane Centre, Copenhagen, 
Denmark). The Mantel–Haenszel random-effect model was used 
for binary end points, and the inverse variance method was used for 
continuous outcomes. In addition, we evaluated subgroup analyses 
according to the following criteria: GERD based on endoscopic 
findings (erosive reflux disease (ERD) vs non-erosive reflux dis-
ease (NERD), refractory GERD vs non-refractory GERD, study 
population (Eastern vs Western), length of treatment (≤ 4 weeks 
vs > 4 weeks), and studies assessed as low RoB vs unclear RoB. 
To determine heterogeneity, we used the I2 test developed by Hig-
gins.18 A P-value of < 0.05 was considered statistically significant. 
The levels of evidence in each outcome were evaluated based on 
the Grading of Recommendations, Assessment, Development, and 




Our primary literature search retrieved a total of 2897 studies, 
of which 2857 were rejected based on the scrutiny of the title and ab-
stract. The remaining 40 articles were subjected to full reviews, and 
after assessing the eligibility, we excluded a further 24 articles (Fig. 1), 
leaving 16 articles10,19-33 for meta-analysis (Table 1). These 16 studies 
presented details on 1446 participants, among whom 719 were in-
cluded in the PPI plus prokinetics group (mosapride,10,21,22,24,25,29-32,34 
domperidone,23,27,28 revexepride,19,20 and acotiamide26) and 727 were 
included in the PPI monotherapy group. Among these 16 stud-
ies, half (8 studies) were rated as having an unclear RoB, whereas 
among the remaining eight studies, 6 and 2 trials were assessed as 
having a low and high RoB, respectively. The authors’ assessments 

































through other sources (n = 0)
Records after duplicates removed (n = 2897)
Records screened (n = 2897)
Full-text articles assessed for eligibility
(n = 40)




No eligible comparison (n = 13)
No extractable data (n = 6)
Used herbal prokinetics (n = 3)
No interested endpoint (n = 2)
Records excluded (n = 2857)
Records identified through
database searching:
PubMed (n = 1146)
EMBASE (n = 1228)
Cochrane library (n = 1685)
Figure 1. Flow diagram of the studies 
included in the meta-analysis.
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Primary and Secondary Outcomes
Nine studies indicated global symptom improvement of 
GERD in terms of a binary outcome (yes or no),10,19,22,24-26,28-30 
whereas the other 7 studies20,21,23,27,31-33 reported continuous mea-
sures (ie, a change in symptom improvement). Among the 9 studies 
that rated global symptom improvement of GERD in terms of a 
binary outcome, the average percentage symptom improvement was 
63.8% in the PPI plus prokinetics group, compared with 50.6% in 
the PPI monotherapy group. The PPI plus prokinetics treatment 
was found to significantly reduce the global symptoms of GERD 
(risk ratio [RR] of reflux symptoms resolution, 1.22; 95% CI, 1.11 
to 1.35; P < 0.0001; number needed to treat [NNT], 7; 95% CI, 
5 to 13 with low heterogeneity [I2 15%]). With respect to indi-
vidual prokinetics, the data were as follows: mosapride (RR, 1.16; 
95% CI, 1.05 to 1.28; NNT, 11; 95% CI, 5 to 51), and prokinetics 
other than mosapride (RR, 1.54; 95% CI, 1.23 to 1.93; NNT, 5; 
95% CI, 4 to 11) (Fig. 2). In the seven trials in which the primary 
outcome was reported as a continuous measure (change in symp-
tom improvement), subgroup analyses also showed a significant im-
provement in the PPI plus prokinetics group (pooled standardized 
mean difference [SMD], 1.38; 95% CI, 0.42 to 2.34) with high 
heterogeneity (Supplementary Fig. 2).
Pooled data from 2 studies (n = 300) which reported the QoL 
scores revealed no significant differences in the QoL scores between 
patients receiving PPI plus prokinetics treatment and PPI mono-
therapy (SMD, 1.22; 95% CI, -1.76 to 4.20; I2, 99%; P = 0.420). 
Pooled data from 8 separate studies (n = 725) which reported AEs 
including 3 different prokinetics (mosapride, domperidone, and 
acotiamide) revealed that AEs were detected in 7.9% of patients in 
the PPI plus prokinetics group compared with 9.2% of patients in 
the PPI monotherapy group. There was no association between a 
specific prokinetic and any particular AE (RR, 0.91; 95% CI, 0.57 
to 1.45; I2, 0%; P = 0.680).
Subgroup Analyses
Erosive reflux disease versus non-erosive reflux disease
Evaluation of the outcomes based on GERD subtype deter-
mined by endoscopic findings was performed in 9 studies. Analysis 
of 4 studies involving 257 participants with the ERD subtype 
showed no significant improvement in patients in the PPI plus 
prokinetics group with moderate heterogeneity. Three studies that 
evaluated patients with the NERD subtype (n = 276) revealed 









Heterogeneity: Tau = 0.00; Chi = 2.27, df = 5 ( = 0.81); I = 0%
Test for overall effect: Z = 3.02 ( = 0.002)
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Total events
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Total events
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Test for overall effect: Z = 3.94 ( < 0.0001)
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Figure 2. Forest plot comparing proton pump inhibitor (PPI) plus prokinetics and PPI monotherapy in patients with gastroesophageal reflux dis-
ease in term of symptom improvement, subgrouped by individual prokinetic.
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no significant difference between the combination treatment with 
PPI plus prokinetics and PPI monotherapy groups with respect to 
relieving the symptoms of reflux, and showed that there was signifi-
cant heterogeneity among these trials. Four trials involving 499 par-
ticipants did not differentiate between GERD subtypes. Subgroup 
analyses in these trials indicated the efficacy of PPI plus prokinetics 
therapy at reducing global GERD symptoms (RR, 1.34; 95% 
CI, 1.15 to 1.57; NNT, 5; 95% CI, 3 to 9) with low heterogeneity 
(Supplementary Fig. 3). 
Refractory gastroesophageal reflux disease versus non-
refractory gastroesophageal reflux disease
Analysis of 2 studies involving 310 participants with refractory 
GERD revealed a significant global symptom improvement in the 
PPI plus prokinetics group (NNT, 5; 95% CI, 3 to 15) with low 
heterogeneity. Seven studies evaluated patients with non-refractory 
GERD (n = 722) and identified a greater likelihood of global 
symptom improvement in patients receiving PPI plus prokinetics 
treatment compared with those receiving PPI monotherapy (NNT, 
8; 95% CI, 5 to 22) with no significant heterogeneity (Fig. 3).
Region of study (Western versus Eastern) 
Two trials with 340 participants were conducted in Western 
countries (the Czech Republic, France, Germany, Hungary, Latvia, 
Poland, Romania, the USA, and Belarus), whereas 7 studies involv-
ing 692 participants were conducted in Asia (Korea, Japan, Taiwan, 
India, and China). Studies from both regions indicated the efficacy 
of PPI plus prokinetics at reducing global GERD symptoms with 
low heterogeneity (Fig. 4). However, the NNT was found to be 
2-fold higher in the Eastern population (10; 95% CI, 5 to 37) than 
that in patients from Western countries (5; 95% CI, 3 to 10).
Length of treatment
Three trials that assessed the efficacy of treatment (PPI plus 
prokinetics treatment or PPI monotherapy) for 4 weeks or less, and 
the included follow-up in 305 individuals revealed no significant 
difference between the PPI plus prokinetics and PPI monotherapy 
groups with respect to relieving the symptoms of GERD, and there 
was a low heterogeneity among these trials. In contrast, among pa-
tients receiving treatment for at least 4 weeks, there was a significant 
reduction in GERD symptoms in patients treated with PPI plus 
prokinetics compared to those treated with PPI monotherapy, (n = 
727) (NNT 6, 95% CI, 4 to 10) (Fig. 5).
Risk of bias (low versus unclear)
Five trials with a low RoB (n = 533) revealed the significant 





Heterogeneity: Tau = 0.00; Chi = 0.43, df = 1 ( = 0.51); I = 0%
Test for overall effect: Z = 3.06 ( = 0.002)
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Figure 3. Forest plot comparing proton pump inhibitor (PPI) plus prokinetics and PPI monotherapy in patients with gastroesophageal reflux dis-
ease in term of symptom improvement, subgrouped by refractoriness of gastroesophageal reflux disease.
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Figure 4. Forest plot comparing proton pump inhibitor (PPI) plus prokinetics and PPI monotherapy in patients with gastroesophageal reflux dis-
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Figure 5. Forest plot comparing proton pump inhibitor (PPI) plus prokinetics and PPI monotherapy in patients with gastroesophageal reflux dis-
ease in term of symptom improvement, subgrouped by length of treatment.
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efficacy of combination treatment with PPI plus prokinetics at 
improving global GERD symptoms. Similarly, 4 studies with 499 
individuals having an unclear RoB revealed significant differences 
between the PPI plus prokinetics and PPI monotherapy arms, with 
a low heterogeneity between the studies (Supplementary Fig. 4).
Quality of Evidence
On comparing the efficacy of the PPI plus prokinetics treat-
ment with that of the PPI monotherapy, GRADE assessment of 
the quality of evidence indicated a moderate effect on reducing 
the global GERD symptoms. This can be attributed to concerns 
regarding the RoB in primary outcome assessments relating to trial 
design (eg, unexplained random sequence generation, allocation 
concealment, and blinding method for participants, medical person-
nel, and outcome assessors). However, the quality of evidence for 
QoL was found to be very low, while for AEs it was low (Table 2). 
Discussion  
GERD is a complex disease characterized by a multifactorial 
pathogenesis. Previously, 60-70%, 20-30%, and 6-10% improve-
ment in the symptoms of GERD in response to PPI treatment 
has been reported in patients with NERD, ERD, and Barrett’s 
esophagus, respectively.2 Given this variable efficacy, agents other 
than PPIs, including histamine H2 receptor antagonists, alginate, 
baclofen, and prokinetics, are often used for treating patients with 
GERD.34 Although the use of prokinetics in North America is 
generally limited, these agents are widely used in patients with func-
tional dyspepsia in Asia. However, evidence regarding the efficacy 
of prokinetics for treating patients with GERD is controversial.
The present systematic review indicate that compared with PPI 
monotherapy, combination treatment with PPI plus prokinetics can 
improve GERD symptoms with a moderate NNT of 7 and low 
heterogeneity. In addition, although only 2 trials were assessed, our 
analysis indicated that in patients with PPI-refractory GERD, PPI 
plus prokinetics treatment showed beneficial effects with low het-
erogeneity with respect to global symptom improvement of GERD 
compared with that observed in response to PPI monotherapy. Our 
analysis identified mosapride, domperidone, acotiamide, and revex-
epride as effective prokinetics in GERD patients when combined 
with PPI therapy. In contrast to the results of a previous meta-
analysis,12 our findings on PPI plus mosapride treatment indicated 
the beneficial effects of prokinetics with respect to reducing GERD 
symptoms. This disparity in assessments can probably be explained 
by our inclusion of 2 studies, involving 232 participants that were 
published subsequent to the publication of the aforementioned 
meta-analysis,29,30 in which combination treatment with PPI plus 
mosapride was found to result in a significant global symptom 
improvement of GERD. Mosapride has the effect of reducing the 
acid reflux by modulating esophageal motility,16 and accordingly, 
mosapride combined with PPI therapy was found to be beneficial 
for enabling relief from GERD symptoms. However, given that the 
assessment of the efficacies of domperidone, acotiamide, and revex-
epride were represented by 1 study each, we were unable to verify 
whether any of these prokinetics are more effective than mosapride 
owing to insufficient evidence. 
With respect to the region of study, trials conducted in both 
Western and Eastern countries have demonstrated the efficacy 
of combination treatment with PPI plus prokinetics at reduc-
ing GERD symptoms. Although only 2 relevant trials have been 
conducted in Western countries, these indicated that the patients 
in these countries (NNT, 5) appear to show a more pronounced re-
sponse to treatment with PPI plus prokinetics treatment compared 
with patients in Eastern countries (NNT, 10). Although we assume 
that these differences in response may be associated with patient-
related factors such as ethnicity, genetics, environment, and culture, 
additional studies in Western countries would be necessary to pro-
vide more supportive evidence in this respect. 
With respect to the length of treatment, patients receiving treat-
ment for ≤ 4 weeks appear to show no significant difference in their 
response to combination treatment with PPI plus prokinetics and 
PPI monotherapy with respect to relief from GERD symptoms. 
However, in patients treated for at least 4 weeks, those receiving 
PPI plus prokinetics therapy were found to show a greater reduc-
tion in GERD symptoms than patients receiving PPI monotherapy. 
Therefore, when physicians prescribe a combination of prokinetics 
and PPI to patients with GERD, a treatment regimen of at least 4 
weeks should be recommended.
With respect to the GERD subtype determined by endoscopic 
findings, studies with the ERD and NERD subtype showed no 
significant difference between the combination treatment with PPI 
plus prokinetics and PPI monotherapy groups with respect to glob-
al symptom improvement. We thought that it was due to the small 
number of studies and more than moderate heterogeneity. 
Although the present study represents the most comprehensive 
review to date on comparison between PPI plus prokinetics therapy 
and PPI monotherapy with respect to the treatment of patients 
with GERD, it does have certain limitations. First, half (8/16) of 
the studies we assessed were rated as having an unclear RoB, and 
thus, at best, the quality of evidence should be considered moder-
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ate. Second, given the limited availability of prokinetics in Western 
countries, we included only 2 relevant studies in the present meta-
analysis. Third, the type of prokinetics was heterogenous. Lastly, 
various methods were used to evaluate primary outcome (global 
symptom improvement of GERD).
Despite the aforementioned limitations, this study can, never-
theless, be considered to have certain strengths. This, to the best of 
our knowledge, is the first meta-analysis to show the superior ef-
ficacy of PPI plus prokinetics treatment with respect to PPI mono-
therapy in patients with GERD. In this respect, current guidelines 
simply recommend the use of prokinetics in combination with PPIs 
in GERD patients who exhibit an insufficient response to PPI 
alone. However, with the exception of studies that have examined 
the effect of individual prokinetics, there is a lack of strong evidence 
regarding the efficacy of these agents in the treatment of patients 
with GERD when used in combination with PPI therapy. The 
findings of this study do, nevertheless, indicate that combination 
treatment with prokinetics and PPI would be beneficial in patients 
with GERD, particularly when this treatment lasts for at least 4 
weeks.
In conclusion, the findings of this study indicate (with a mod-
erate level of evidence) the benefits of combining prokinetics with 
PPI therapy for treating GERD. Although the data we assessed 
were insufficient to identify the type(s) of prokinetics that would be 
the most effective, we found that the combination of prokinetics and 
PPI appears to reduce the symptoms of GERD in patients who are 
unresponsive to PPI monotherapy. 
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